Drawing for GENEA BIOMEDX GEMS

USPTO serial 79171360

GENEA BIOMEDX GEMS

Reviewed by CopyMark Law Group

Reg. 5029077Status 706Renewal
Filing date
Status date
Registration date
Aug 30, 2016
Examiner
MITTLER, ROBIN M
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with GENEA BIOMEDX GEMS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $1,700

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Eric Lamb

Eric Lamb FBT Gibbons LLP111 Monument CircleSuite 4500INDIANAPOLIS, IN 46204

Goods and services

ClassDescriptionStatusFirst use
001Cell culture media other than for medical or veterinary use, namely, for laboratory use in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation; cell culture media other than for medical or veterinary use, namely, for scientific and research use in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation; human cell products, namely, pluripotent and differentiated human cells and stem cells for research or scientific purposes; human cell products, namely, pluripotent and differentiated human cells and stem cells for laboratory use excluding medical and veterinary use; biological and chemical products and substances for scientific use other than for medical or veterinary use, namely, chemicals for use in science in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation, chemical preparations for scientific purposes in relation to researching, diagnosing and/or treating infertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivation, biological preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical reagents for scientific use in relation to researching, diagnosing and/or treating fertility and other disorders relating to fertility and reproduction and in relation to researching and/or undertaking cell fertilisation, division and cultivationACTIVE—
005Culture media for medical use for use to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes for medical purposes; cell culture media for medical use for use to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes for medical purposes; human cell products, namely, pluripotent and differentiated human cells and stem cells for medical or clinical use; cell culture media for use in medical or medical research applications for cultivating human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes; biological and chemical products and substances for medical use excluding dietary supplements, nutritional supplements, vaccines and antibiotics, namely, chemicals for medical or clinical use in relation to assisted reproductive therapies, cell fertilisation, cell division and cell cultivation and diagnosing and/or treating fertility and other disorders relating to fertility and reproduction, chemical preparations for medical or clinical use in relation to assisted reproductive therapies, cell fertilisation, cell division and cell cultivation and diagnosing and/or treating fertility and other disorders relating to fertility and human reproduction, chemical preparations for the treatment of infertility and other disorders relating to fertility and human reproduction, biological preparations for the treatment of infertility and other disorders relating to fertility and human reproduction, biological preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical preparations to support growth of human cells, human embryos, human reproductive tissue, human sperm, human blastocysts or human oocytes, chemical reagents for medical use in relation to assisted reproductive therapies, cell fertilisation, cell division and cell cultivation and diagnosing and/or treating fertility and other disorders relating to fertility and reproduction; pharmaceutical preparations for the treatment of infertility and other disorders relating to fertility and human reproduction, excluding dietary supplements, nutritional supplements, vaccines and antibioticsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 20, 2026NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Oct 20, 202671AGREGISTERED-SEC.71 ACCEPTED—
Oct 19, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 16, 2026ES71TEAS SECTION 71 RECEIVED—
Aug 30, 2025REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jul 3, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
Sep 8, 2023NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Sep 8, 202371AGREGISTERED-SEC.71 ACCEPTED—
Sep 7, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Feb 20, 2023ES71TEAS SECTION 71 RECEIVED—
Jan 7, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 30, 2021REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Feb 15, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jan 18, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 18, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 17, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 1, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 1, 2017FIMPFINAL DISPOSITION PROCESSED—
Nov 30, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 30, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 22, 2016OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 13, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 14, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 1, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jun 1, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
May 25, 2016NPUBNOTICE OF PUBLICATION—
May 7, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 7, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 7, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 7, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 24, 2015RFNTREFUSAL PROCESSED BY IB—
Oct 8, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 8, 2015RFRRREFUSAL PROCESSED BY MPU—
Oct 7, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 6, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 22, 2015DOCKASSIGNED TO EXAMINER—
Sep 8, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 2, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 27, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance